Myovant Sciences Ltd (NYSE: MYOV), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapies for women's health and endocrine diseases, announced yesterday that it has named Kim Sablich as its new chief commercial officer.
Sablich was vice president of Primary Care Marketing in the United States for GlaxoSmithKline. Prior to that, she was vice president, Global Medicines Commercialisation in the United Kingdom, and before that, vice president, Vaccines Commercial Strategies. Before joining GSK, she spent 15 years at Merck, where she held positions of increasing responsibility in the commercial organisation across sales, product management, pricing/access, and customer insights, with a focus on the cardiovascular, respiratory and vaccines business areas. She has extensive experience in direct-to-consumer marketing, having led the development of consumer strategies and national multi-channel campaigns for multiple products. She is currently a member of the board of directors of AllerGenis LLC.
She earned a BA from Denison University and an MBA from The Wharton School of the University of Pennsylvania.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine